Modern and Promising Strategies for Treatment of Alopecia in the United States: Clinical and Pharmacological, Marketing, Regulatory, SWOT Analysis
SSP Modern Pharmacy and Medicine · 2025
DOI: 10.53933/943cpk09 ↗Kurz gefasst
Fachartikel in der Zeitschrift SSP Modern Pharmacy and Medicine, 2025. Verfasst von Khrystyna Malaniuk. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Alopecia is a common chronic condition that has a significant medical and social impact, including on the psychological comfort and quality of life of patients. The most common forms are androgenetic and alopecia areata. Treatment includes both drugs approved by the US Food and Drug Administration (FDA) and cosmetics without regulatory approval. Despite progress in pharmacotherapy, the problem of complete and stable hair restoration remains relevant. The aim is to comprehensively analyze modern drugs for the treatment of alopecia used in the US, taking into account their clinical and pharmacological efficacy, safety, economic availability, regulatory status and market development prospects. An analytical review was conducted using FDA data, scientific publications, official sources of manufacturers, price aggregators (GoodRx, Drugs.com). The objects of analysis were six FDA-approved drugs (minoxidil, finasteride, triamcinolone, clobetasol, baricitinib, ritlecitinib) and one cosmetic product without FDA approval (HydraFacial Keravive Peptide Complex). Clinical-pharmacological, documentary, regulatory, comparative, marketing and SWOT analysis of market trends were applied. It was found that minoxidil and finasteride remain the most affordable and have a significant evidence base of effectiveness. JAK inhibitors (baricitinib, rituximab) demonstrate high clinical results in patients with alopecia areata. However, their cost significantly exceeds the average level of financial capabilities of most patients. Corticosteroids (triamcinolone, clobetasol) retain an important role in the treatment of inflammatory forms of alopecia. Cosmetic products, in particular Keravive Serum, are used as additional methods to improve the condition of the scalp and stimulate hair growth. SWOT analysis revealed the market strengths (availability of drugs with proven efficacy), weaknesses (high cost of innovative drugs), opportunities (development of combination therapy, telemedicine and telepharmacy) and threats (regulatory restrictions, economic barriers to accessibility). The market for alopecia treatment in the US is characterized by a combination of traditional and innovative products. The most promising areas of development are the introduction of innovative drugs (in particular, JAK inhibitors), combined treatment regimens, as well as expanding access to therapy using telemedicine, telepharmacy and online pharmacies. To increase the effectiveness of treatment, individualization of therapeutic strategies is necessary, taking into account the clinical form of alopecia, the patient's financial capabilities and the prognosis for response to treatment.
Zitieren
APA
Malaniuk, K. (2025). Modern and Promising Strategies for Treatment of Alopecia in the United States: Clinical and Pharmacological, Marketing, Regulatory, SWOT Analysis. SSP Modern Pharmacy and Medicine. https://doi.org/10.53933/943cpk09
Vancouver
Malaniuk K. Modern and Promising Strategies for Treatment of Alopecia in the United States: Clinical and Pharmacological, Marketing, Regulatory, SWOT Analysis. SSP Modern Pharmacy and Medicine. 2025. doi:10.53933/943cpk09
BibTeX
@article{Malaniuk2025,
author = {Malaniuk, Khrystyna},
title = {Modern and Promising Strategies for Treatment of Alopecia in the United States: Clinical and Pharmacological, Marketing, Regulatory, SWOT Analysis},
journal = {SSP Modern Pharmacy and Medicine},
year = {2025},
doi = {10.53933/943cpk09}
}
EUVIMED